Merck No Longer in Talks to Buy Revolution Medicines

2026-01-25 | original

read original get Medicines → more articles

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.

Explore topics: acquire acquire revmed billion biotech biotech billion